Co-Diagnostics (CODX) announced a private placement agreement with institutional investors to sell 1.65M shares of common stock, or pre-funded warrants in lieu of shares, along with warrants to ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...

The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded ...

May 14, 2026 at 4:30 p.m. ET. CALL PARTICIPANTS. Chief Executive Officer — Dwight Egan; Chief Financial Officer — Brian Brown ...

On India, (Chairman, CEO & President Dwight Egan) said, "CoSara has a nationwide commercial presence, has served hundreds of laboratory customers and has 15 clinical laboratory PCR tests cleared by ...

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing. The agreement aims ...

The molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ ...

CoDiagnostics, Inc. (CODX) closed at $25.73 in the latest trading session, marking a -1.61% move from the prior day. This move lagged the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.17% ...